Literature DB >> 2421272

Cerebrospinal fluid studies of monoamine metabolism in schizophrenia.

D P van Kammen, J Peters, W B van Kammen.   

Abstract

The authors review the studies of spinal fluid monoamines and their metabolites with and without probenecid and during drug-free and medicated conditions. Although technical knowhow and understanding of the variable that influence the actual levels measured has dramatically increased over the last 20 years, many questions still remain. Despite or rather because of advances such as CT, PET, and MRI, CSF studies still carry great promise for understanding the illness, predicting drug response, and behavioral change following drug withdrawal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421272

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  5 in total

1.  Facilins, a novel class of biological factors that facilitate the aortic response to dopamine and other biogenic amines.

Authors:  B Silvestrini; M Palmery; L Tolu; F Basta; M G Leone; C Y Cheng
Journal:  J Neural Transm Gen Sect       Date:  1994

2.  Clozapine pharmacology and tardive dyskinesia.

Authors:  J Lieberman; C Johns; T Cooper; S Pollack; J Kane
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Peripheral and central adrenoceptor modulation of the behavioural effects of clozapine in the paw test.

Authors:  E P Prinssen; B A Ellenbroek; A R Cools
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

Review 4.  The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system.

Authors:  D C Ohuoha; T M Hyde; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Medial septum activation produces opposite effects on dopamine neuron activity in the ventral tegmental area and substantia nigra in MAM vs. normal rats.

Authors:  David M Bortz; Anthony A Grace
Journal:  NPJ Schizophr       Date:  2018-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.